U.S. markets closed

Maravai LifeSciences Holdings, Inc. (MRVI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.50+0.61 (+4.39%)
At close: 04:00PM EST
14.68 +0.18 (+1.24%)
After hours: 06:23PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close13.89
Bid14.44 x 900
Ask14.78 x 800
Day's Range13.73 - 14.76
52 Week Range12.16 - 41.82
Avg. Volume1,987,955
Market Cap3.701B
Beta (5Y Monthly)-0.26
PE Ratio (TTM)7.71
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
120% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for MRVI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Maravai LifeSciences Holdings,
    NARI: Lowering target price to $64.00INARI MEDICAL INC has an Investment Rating of HOLD; a target price of $64.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Motley Fool

    3 Great Growth Stocks Down 20% or More to Buy Now

    Three Motley Fool contributors were asked to identify great growth stocks down 20% or more to buy now. Here's why they chose Beam Therapeutics (NASDAQ: BEAM), Maravai LifeSciences (NASDAQ: MRVI), and Novavax (NASDAQ: NVAX). Keith Speights (Beam Therapeutics): Beam Therapeutics was flying high in the early part of 2021.

  • Motley Fool

    3 Biopharma Stocks That Could Help Make You a Fortune

    As any biotech investor will tell you freely, investing in biopharma is rife with risks. Clinical trials can miss the mark, and successful medicines on the market can get outcompeted by newer entrants. To do that, they tend to have a mix of reliable sales alongside a bunch of ambitious projects to provide upside.

  • Insider Monkey

    10 Best Medical Stocks Under $20

    In this article, we discuss 10 best medical stocks under $20. If you want to see more stocks in this selection, check out 5 Best Medical Stocks Under $20. The healthcare industry has undergone a significant restructuring in the wake of the COVID-19 pandemic. There were multiple new healthcare trends in 2022 that have a […]